Bausch Health Companies Inc.

DB:BVF Stock Report

Market Cap: €2.8b

Bausch Health Companies Valuation

Is BVF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BVF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BVF (€8.66) is trading below our estimate of fair value (€55.67)

Significantly Below Fair Value: BVF is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for BVF?

Key metric: As BVF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for BVF. This is calculated by dividing BVF's market cap by their current revenue.
What is BVF's PS Ratio?
PS Ratio0.3x
SalesUS$9.47b
Market CapUS$2.99b

Price to Sales Ratio vs Peers

How does BVF's PS Ratio compare to its peers?

The above table shows the PS ratio for BVF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.9x
DMP Dermapharm Holding
1.7x4.1%€2.0b
BAYN Bayer
0.4x1.0%€18.8b
PSG PharmaSGP Holding
2.8x7.7%€304.6m
MRK Merck KGaA
2.9x4.1%€61.7b
BVF Bausch Health Companies
0.3x1.5%€3.0b

Price-To-Sales vs Peers: BVF is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (2x).


Price to Sales Ratio vs Industry

How does BVF's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

24 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.2.9x3.4%
BVF Bausch Health Companies
0.3x1.5%US$2.99b
BVF 0.3xIndustry Avg. 2.9xNo. of Companies33PS0612182430+
24 CompaniesEstimated GrowthMarket Cap
Industry Avg.2.9x21.3%
BVF Bausch Health Companies
0.3x218.3%US$2.99b
No more companies

Price-To-Sales vs Industry: BVF is good value based on its Price-To-Sales Ratio (0.3x) compared to the European Pharmaceuticals industry average (2.9x).


Price to Sales Ratio vs Fair Ratio

What is BVF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BVF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BVF's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BVF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
€7.91
0%
36.8%€11.07€2.77n/a7
Nov ’25€7.39
€7.62
+3.1%
35.2%€11.03€2.76n/a7
Oct ’25n/a
€7.17
0%
32.0%€10.75€2.69n/a8
Sep ’25n/a
€7.21
0%
31.5%€10.98€2.75n/a8
Aug ’25€5.43
€7.93
+46.2%
35.7%€12.05€2.78n/a8
Jul ’25€6.26
€9.09
+45.1%
20.0%€12.07€6.50n/a7
Jun ’25€5.58
€9.09
+62.8%
20.0%€12.07€6.50n/a7
May ’25€7.97
€9.68
+21.5%
26.9%€14.96€6.54n/a7
Apr ’25€8.70
€9.05
+4.1%
30.6%€14.80€6.48n/a7
Mar ’25€8.41
€9.05
+7.6%
30.6%€14.80€6.48n/a7
Feb ’25€7.20
€8.71
+21.0%
33.6%€14.66€5.50n/a7
Jan ’25€6.90
€8.71
+26.2%
33.6%€14.66€5.50n/a7
Dec ’24n/a
€8.71
0%
33.6%€14.66€5.50n/a7
Nov ’24€6.23
€8.91
+43.1%
33.6%€15.00€5.63€7.397
Oct ’24n/a
€9.12
0%
32.6%€15.13€5.68n/a7
Sep ’24n/a
€7.87
0%
20.6%€11.11€5.55n/a7
Aug ’24€8.45
€7.75
-8.3%
20.8%€10.85€5.42€5.437
Jul ’24n/a
€7.79
0%
22.5%€10.99€5.50€6.266
Jun ’24n/a
€11.40
0%
82.7%€32.36€5.55€5.586
May ’24€6.31
€11.86
+88.1%
75.2%€31.72€6.34€7.976
Apr ’24n/a
€13.06
0%
75.3%€32.65€6.53€8.705
Mar ’24n/a
€12.57
0%
73.1%€32.99€6.60€8.416
Feb ’24€7.49
€11.37
+51.8%
81.0%€33.16€5.68€7.207
Jan ’24€5.79
€11.46
+97.9%
81.0%€33.43€5.73€6.907
Dec ’23n/a
€12.04
0%
81.0%€35.13€6.02n/a7
Nov ’23€6.48
€12.89
+99.1%
90.7%€40.56€5.07€6.237

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies